LUNG CANCER
Latest News
Advertisement
Latest Videos
Advertisement
More News
Supplemental Biologics License Applications (sBLAs) were sent to and accepted by the FDA for a new dosing schedule for nivolumab (Opdivo) across all of the agent's indications as a montherapy, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given its support on indications for atezolizumab (Tecentriq) in non–small cell lung cancer (NSCLC) and urothelial carcinoma.
Treatment of BRAF Mutated Non-Small Cell Lung Cancer
Treatment of ALK+ Non-Small Cell Lung Cancer
In a 17-0 vote, the FDA’s Oncologic Drugs Advisory Committee unanimously recommended the approval of ABP-215, a biosimilar for bevacizumab.
Martin Gutierrez, MD, director, drug discovery/phase I unit, medical oncologist, thoracic and gastrointestinal oncology, John Theurer Cancer Center, discusses results for durvalumab (Imfinzi) for the treatment of non-small cell lung cancer.
Matthew D. Hellmann, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CheckMate-032 study, which explored nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).
A look back at all the FDA news that happened in the month of June, including in multiple myeloma, hematology, sarcoma, and lung cancer.
Solange Peters, MD, PhD, has been elected the president of the European Society for Medical Oncology (ESMO) for the 2020-2021 term.
Ceritinib has been approved by the European Union (EU) for the first-line treatment of patients with <em>ALK</em>-positive advanced non­–small cell lung cancer.
A retrospective analysis suggests that treatment with a MET tyrosine kinase inhibitor can prolong survival in patients with advanced non–small cell lung cancer with a <em>MET</em> exon 14 mutation.
The combination of dabrafenib (Tafinlar) and trametinib (Mekinist) has been approved by the FDA for the treatment of patients with <em>BRAF</em> V600–positive advanced or metastatic non–small cell lung cancer (NSCLC).
Mark Awad, MD, PhD, medical oncologist, Dana-Farber Cancer Institute, discusses the impact of MET inhibitors on survival among patients with <em>MET</em> exon 14-mutant non–small cell lung cancer.
The risk of disease progression was reduced by more than 40% and there was an average 6.5-month improvement in response duration with the second-generation EGFR inhibitor dacomitinib compared with gefitinib as a first-line treatment for patients with advanced, <em>EGFR</em>-mutant non–small cell lung cancer.
Leena Gandhi, MD, PhD, director of the Thoracic Medical Oncology Program at NYU Langone School of Medicine, discusses first-line carboplatin and pemetrexed with or without pembrolizumab for advanced nonsquamous non–small cell lung cancer.
The antibody-drug conjugate sacituzumab govitecan was well-tolerated and produced a median duration of response of 6.0 months in previously treated patients with metastatic non–small cell lung cancer.
Advertisement
Advertisement